Raras
Buscar doenças, sintomas, genes...
Pustulose exantemática generalizada aguda
ORPHA:293173CID-10 · L27.0DOENÇA RARA

Uma erupção na pele que surge de repente e se espalha pelo corpo todo, caracterizada por febre e várias bolinhas pequenas cheias de pus sobre uma área avermelhada.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Uma erupção na pele que surge de repente e se espalha pelo corpo todo, caracterizada por febre e várias bolinhas pequenas cheias de pus sobre uma área avermelhada.

Publicações científicas
1.007 artigos
Último publicado: 2026 Apr 13

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
Unknown
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.0
Worldwide
Início
All ages
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: L27.0
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🩸
Sangue
8 sintomas
🧬
Pele e cabelo
3 sintomas
🫃
Digestivo
2 sintomas
🫁
Pulmão
1 sintomas
🫘
Rins
1 sintomas
👁️
Olhos
1 sintomas

+ 6 sintomas em outras categorias

Características mais comuns

90%prev.
Pústula
Muito frequente (99-80%)
90%prev.
Leucocitose
Muito frequente (99-80%)
55%prev.
Taxa de sedimentação de eritrócitos elevada
Frequente (79-30%)
55%prev.
Neutrofilia
Frequente (79-30%)
55%prev.
Descamação da pele
Frequente (79-30%)
55%prev.
Eosinofilia
Frequente (79-30%)
23sintomas
Muito frequente (2)
Frequente (7)
Ocasional (10)
Muito raro (4)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 23 características clínicas mais associadas, ordenadas por frequência.

PústulaPustule
Muito frequente (99-80%)90%
LeucocitoseLeukocytosis
Muito frequente (99-80%)90%
Taxa de sedimentação de eritrócitos elevadaElevated erythrocyte sedimentation rate
Frequente (79-30%)55%
NeutrofiliaNeutrophilia
Frequente (79-30%)55%
Descamação da peleScaling skin
Frequente (79-30%)55%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.007PubMed
Últimos 10 anos200publicações
Pico202571 papers
Linha do tempo
2026Hoje · 2026🧪 2014Primeiro ensaio clínico📈 2025Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

🧬

Nenhum gene associado encontrado

Os dados genéticos desta condição ainda estão sendo catalogados.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
·Pré-clínico3
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 3 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Pustulose exantemática generalizada aguda

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

3 ensaios clínicos encontrados.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
576 papers (10 anos)
#1

Acute Generalized Exanthematous Pustulosis in a Neonate Following Hepatitis B Vaccination: A Case Report.

Sage open pediatrics2026

Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous adverse reaction in neonates and is most commonly drug-induced. Vaccine-associated cases are uncommon in this age group. We report a term male neonate who developed clusters of non-follicular pustules on erythematous plaques approximately 6 hours after receiving a birth dose of hepatitis B vaccine. The infant remained clinically stable, without fever or systemic involvement, and had no exposure to concomitant medications. The rapid onset following a single exposure, characteristic morphology, and prompt resolution were highly suggestive of AGEP. Laboratory investigations and skin biopsy were not performed due to rapid clinical improvement. Infectious etiologies and transient neonatal pustular dermatoses were considered less likely based on the clinical course. Patch testing with the same vaccine lot was positive, supporting a type IV hypersensitivity mechanism. The eruption resolved almost completely within 48 hours with topical hydrocortisone, without complications or recurrence.

#2

The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.

Cureus2026 Mar

Drug hypersensitivity reactions are a clinically significant and potentially preventable cause of hospital admission, treatment interruption, and drug-related mortality worldwide. Within severe cutaneous adverse reactions (SCARs), a group that includes Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS), DRESS stands out because of its delayed onset, multi-organ involvement, and frequent diagnostic uncertainty. Allopurinol is a commonly prescribed medication for hyperuricemia, but in rare cases, it can trigger DRESS. This systematic review was conducted to comprehensively summarize the demographic characteristics, clinical manifestations, diagnostic features, management strategies, and outcomes of reported cases of allopurinol-induced DRESS syndrome. Available case reports and case series were analyzed to consolidate patient characteristics, patterns of organ involvement, treatment approaches, and clinical outcomes. The findings indicate that allopurinol-induced DRESS most often presents with cutaneous manifestations and systemic involvement, most commonly affecting the liver and kidneys, and is associated with considerable morbidity and mortality despite treatment. These results emphasize the importance of early recognition, prompt drug discontinuation, and cautious prescribing of allopurinol, particularly in high-risk populations.

#3

A Systematic Review of Pediatric Acute Generalized Exanthematous Pustulosis.

Pediatric dermatology2026 Mar 09

Acute generalized exanthematous pustulosis (AGEP) is a rare severe cutaneous adverse reaction in children. In this systematic review of 47 cases, a male predominance was observed, and medications remained the most common trigger for AGEP, with a higher contribution from infectious etiologies compared with frequencies reported in adult studies. Management primarily involved cessation of the inciting drug, topical corticosteroids, and supportive care. These findings provide practical guidance for early recognition and evaluation of pediatric AGEP.

#4

Acute Generalized Exanthematous Pustulosis: An Integrated Study of 503 Cases with Emphasis on Drug Culprits, Clinical Features, Diagnosis and Treatment.

Journal of inflammation research2026

Acute generalized exanthematous pustulosis (AGEP) is a drug-induced severe cutaneous adverse reaction (SCAR) characterized by an acute extensive erythematous pustular eruption. Integrated analyses including Asian cohorts remain scarce. A total of 503 AGEP cases were analyzed by combining two distinct, routinely-collected data cohorts: (1) a literature-derived cohort (PubMed, Embase, Web of Science, and CNKI) and (2) a hospital-based clinical cohort from a tertiary-care center in China. The hospital cohort data were collected retrospectively from January 2015 to July 2025. Demographic, etiologic, clinical, laboratory and therapeutic characteristics were summarized. Drugs were stratified by median latency (3 days) into short- versus long-latency groups to explore class-specific patterns. Drugs triggered 94.6% of cases, mainly β-lactam antibiotics (20.7%), non-β-lactam antibiotics (16.3%), and hydroxychloroquine (10.4%). With a 3-day median latency threshold, antibiotic-related reactions showed short latency, whereas antimalarials, analgesics, and antifungals exhibited longer latency. Hospitalization occurred in 75.1%, and systemic involvement in 20.2% (mostly hepatic or renal). Mucosal lesions were infrequent (oral 8.7%, genital 1.8%). Among those tested, patch tests were positive in 71.6%. Systemic corticosteroids were the mainstay (63.8%) of treatment, with cyclosporine (3.7%) and intravenous immunoglobulin (2.5%) used as adjuncts. A few refractory cases received biologics, including IL-17 inhibitors (eg secukinumab, brodalumab) and IL-36 receptor blockade (spesolimab), achieving partial or complete response. Eight deaths (1.6%) were documented, mainly among older, comorbid, polymedicated patients. AGEP displays distinct drug class-specific latency signatures and occasional systemic morbidity. We propose a conceptual AGEP causality triage framework integrating latency and allergologic evidence to enhance culprit identification in polypharmacy settings. Given the mechanistic involvement of the IL-36-Th17/IL-17 axis, biologic agents targeting IL-17 or IL-36 pathways show promise in severe or corticosteroid-refractory AGEP, warranting confirmation in larger prospective studies.

#5

Iodinated Contrast-Induced AGEP and ALEP: Recognition, Diagnosis, and Management.

International journal of dermatology2026 Feb 22

Acute generalized exanthematous pustulosis (AGEP) and acute localized exanthematous pustulosis (ALEP) are rare T-cell-mediated hypersensitivity reactions most commonly triggered by medications but increasingly recognized after exposure to iodinated contrast media (ICM). With the growing use of contrast-enhanced imaging, clinicians are more frequently faced with diagnostic and management challenges in patients with suspected ICM-induced reactions and with decisions regarding future contrast exposure. This systematic review aimed to synthesize published cases of ICM-associated AGEP and ALEP, with a particular focus on clinical recognition, diagnostic evaluation in routine practice, acute management, and implications for future imaging. The review was registered in PROSPERO (CRD420251140990). Searches of PubMed/MEDLINE, Web of Science, and the Serbian Citation Index (SCIndeks) were conducted without language or date restrictions through September 9, 2025, supplemented by backward and forward citation searching. Thirty-one publications reporting 53 patients were included. Patient age ranged from 4 to 93 years (median 56 years), and most were female (64.1%). AGEP accounted for 96.2% of cases, while ALEP was rare (3.8%). AGEP was associated with iomeprol, iodixanol, iohexol, iopromide, ioversol, iopamidol, and iobitridol. ALEP was linked to iomeprol and ioversol. Onset was typically rapid, with a median of 1 day after ICM exposure. Recurrent reactions occurred in 18.9% of patients, often with shorter latency upon re-exposure. Reported management most frequently involved topical corticosteroids, systemic corticosteroids, and antihistamines. Nearly all patients (98.1%) recovered. Clinicians should recognize ICM as potential triggers of AGEP and ALEP and pursue appropriate diagnostic evaluation and allergological assessment to guide safe future imaging.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC702 artigos no totalmostrando 196

2026

The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.

Cureus
2026

A Systematic Review of Pediatric Acute Generalized Exanthematous Pustulosis.

Pediatric dermatology
2026

Acute Generalized Exanthematous Pustulosis: An Integrated Study of 503 Cases with Emphasis on Drug Culprits, Clinical Features, Diagnosis and Treatment.

Journal of inflammation research
2026

Acute Generalized Exanthematous Pustulosis in a Neonate Following Hepatitis B Vaccination: A Case Report.

Sage open pediatrics
2026

Iodinated Contrast-Induced AGEP and ALEP: Recognition, Diagnosis, and Management.

International journal of dermatology
2026

Azathioprine-induced acute generalized exanthematous pustulosis in a woman with autoimmune hepatitis.

Dermatology reports
2026

Carbamazepine-induced acute generalized exanthematous pustulosis triggering diabetic ketoacidosis in a patient with type II diabetes mellitus: a case report.

Annals of medicine and surgery (2012)
2026

Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report.

Cureus
2025

Clinical differentiation between acute generalized exanthematous pustulosis and generalized pustular psoriasis: A multi-center study.

Chinese medical journal
2026

Serum neutrophil gelatinase-associated lipocalin as a potential signature for acute generalized exanthematous pustulosis and generalized pustular psoriasis: A case-control study.

JAAD international
2026

Optimizing the EuroSCAR criteria for acute generalized exanthematous pustulosis: A streamlined diagnostic model.

Journal of the American Academy of Dermatology
2025

A real-world pharmacovigilance study of FDA adverse event reporting system events for cefazolin.

Medicine
2026

A novel case of acute localized and generalized exanthematous pustulosis following IL-2 analogue injection amplified by immune checkpoint inhibition.

JAAD case reports
2025

Case Report: Acute generalized exanthematous pustulosis with psoriasis successfully treated with Secukinumab.

Frontiers in immunology
2025

Cross-spectrum efficacy of spesolimab in IL-36-mediated dermatoses: a 'case study.

The Journal of dermatological treatment
2025

Acute Generalized Exanthematous Pustulosis Mimicking Toxic Shock Syndrome in a Pediatric Patient.

Pediatric dermatology
2025

Hydroxychloroquine-Induced Acute Generalized Exanthematous Pustulosis.

The Journal of rheumatology
2025

Etoricoxib and its hidden risks: a case-based review of dermatological, hematological, and cardiovascular complications.

EXCLI journal
2025

Skin-adverse drug reactions in the elderly: An underestimated and avoidable issue.

Annales de dermatologie et de venereologie
2025

Ampicillin-induced Acute Generalized Exanthematous Pustulosis in a Neonate: A Rare Cutaneous Adverse Reaction.

Acta dermato-venereologica
2026

Letter: Propranolol-Induced Acute Generalized Exanthematous Pustulosis Confirmed by Patch Testing: A Case Report.

Dermatitis : contact, atopic, occupational, drug
2025

Acute Generalized Exanthematous Pustulosis Secondary to Application of Tapinarof Cream 1.

Cutis
2025

Risk Factors for Drug-Induced Acute Generalized Exanthematous Pustulosis(AGEP) from 2004 to 2024: A Real-World Study Based on the FAERS.

Clinical, cosmetic and investigational dermatology
2025

A real-world data analysis of piroxicam in the FDA Adverse Event Reporting System (FAERS) database.

Frontiers in medicine
2025

Acute Generalized Exanthematous Pustulosis Linked to Iodinated Contrast Agent Iomeprol.

Indian dermatology online journal
2024

ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS (AGEP) CAUSED BY ANTIBIOTIC POLYTHERAPY: A CASE REPORT.

Acta clinica Croatica
2026

Quality of life in hospitalized patients with acute generalized exanthematous pustulosis: A prospective qualitative study.

Journal of the American Academy of Dermatology
2025

Acute Generalized Exanthematous Pustulosis: A Case Report.

Cureus
2025

Hospitalized generalized pustular psoriasis vs. acute generalized exanthematous pustulosis: A comprehensive analysis of clinical manifestations and treatment outcomes.

Chinese medical journal
2025

A Rare Presentation of Acute Generalized Exanthematous Pustulosis With Refractory Shock.

Cureus
2025

Pustular reaction in adult-onset immunodeficiency due to anti-interferon-gamma autoantibodies.

Frontiers in immunology
2026

Acute generalized exanthematous pustulosis: 15-year retrospective multicentre experience.

Clinical and experimental dermatology
2025

Antibiotics, analgesics and antifungals are commonly implicated in acute generalized exanthematous pustulosis; a retrospective analysis of 1410 cases.

Clinical and experimental dermatology
2025

Iomeprol-induced acute generalised exanthematous pustulosis (AGEP).

BMJ case reports
2026

Penicillin Treatment in Infectious Mononucleosis May Lead to Persistent Drug Allergy in Adolescents and Adults Even after Years.

International archives of allergy and immunology
2025

Combination testing confirming clindamycin induced acute generalized exanthematous pustulosis.

JAAD case reports
2025

Case Report: Infliximab for hydroxychloroquine-induced AGEP with IL17A and IL36RN mutations: a case report and management considerations.

Frontiers in pharmacology
2025

A Rare, Cephalosporin-induced Rash: Acute Generalized Exanthematous Pustulosis.

Journal of community hospital internal medicine perspectives
2025

Severe cutaneous adverse reactions associated with novel antiandrogens: A disproportionality analysis of three databases.

International journal of cancer
2025

Acute generalized exanthematous pustulosis triggered by dupilumab.

Dermatology reports
2025

Achieving Therapeutic Success with Spesolimab: Two Cases of Drug-Induced Generalized Pustular Psoriasis Initially Mimicking Acute Generalized Exanthematous Pustulosis.

Journal of inflammation research
2025

A case of acute generalized exanthematous pustulosis following administration of nemolizumab.

JAAD case reports
2025

Letter: when a Spider Bite Triggers a Dual Immune Response: Acute Generalized Exanthematous Pustulosis and Coombs-Positive Hemolytic Anemia.

Dermatitis : contact, atopic, occupational, drug
2025

Piperacillin-Tazobactam-Induced Generalized Exanthematous Pustulosis.

Cureus
2025

Evaluation of combination therapy with secukinumab and systemic corticosteroids for acute generalized exanthematous pustulosis: A retrospective cohort study.

Journal of the American Academy of Dermatology
2025

Acute Generalized Exanthematous Pustulosis With Negative Patch Test and Drug-Induced Lymphocyte Stimulation Test (DLST) Results: A Case Report.

Cureus
2025

Acute Generalized Exanthematous Pustulosis.

Journal of cutaneous medicine and surgery
2025

Acute generalized exanthematous pustulosis associated with human parvovirus B19 infection.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
2025

Mental health and psychosocial outcomes in survivors of severe cutaneous adverse reactions: a scoping review.

Clinical and experimental dermatology
2025

Acute generalized exanthematous pustulosis induced by iodinated contrast media: a case report.

Dermatology reports
2025

Effective Spesolimab Treatment for Generalized Pustular Psoriasis Masquerading as Acute Generalized Exanthematous Pustulosis: A Case Report.

Cureus
2025

Mosquito Bite as a Potential Novel Trigger for Acute Generalized Exanthematous Pustulosis (AGEP): A Case Report.

Cureus
2025

Diseases of the IL-36 pathway.

The Journal of allergy and clinical immunology
2025

Gabapentin for refractory pruritus in severe cutaneous adverse reactions.

JAAD case reports
2025

Comparison of Acute Generalized Exanthematous Pustulosis with Maculopapular Rash in a Swiss Patient Cohort: A Single-Center Retrospective Study.

Dermatology (Basel, Switzerland)
2025

Acute Generalized Exanthematous Pustulosis in a Patient Treated With Bendamustine-Brentuximab Vedotin.

Dermatitis : contact, atopic, occupational, drug
2025

Acute Generalized Exanthematous Pustulosis Associated With Herpes Simplex Virus Reactivation Due to Cold Medicine: A Case Report and Review of the Literature.

Cureus
2025

Acute Generalized Exanthematous Pustulosis Associated With Human Parvovirus B19 in an 11-Year-Old Girl.

Pediatric dermatology
2025

Acute Generalized Exanthematous Pustulosis Following the Administration of Cephalexin: A Case Report and Review of the Literature.

Cureus
2025

Demographics, Overlap, and Latency of Severe Cutaneous Adverse Reactions in an FDA Database.

medRxiv : the preprint server for health sciences
2025

When Treatment Backfires: A Case Report of Sulfasalazine-Induced Hypersensitivity Syndrome in a Moroccan Patient With Crohn's Disease and Literature Review.

Cureus
2025

Acute Generalized Exanthematous Pustulosis in a 76-year-Old Man With Neuroendocrine Carcinoma of the Lung, Responsive to Ixekizumab.

Clinical, cosmetic and investigational dermatology
2025

Rapid drug desensitization in seven patients with delayed hypersensitivity reactions to biologics and targeted therapies: Reason, successes, and failures.

Allergy and asthma proceedings
2025

Single-cell immunopathology of recurrent acute generalized exanthematous pustulosis associated with vancomycin.

The journal of allergy and clinical immunology. Global
2025

Severe Cutaneous Adverse Reactions Associated with Immune Checkpoint Inhibitors: A Systematic Review of Clinical Characteristics and Management.

Journal of cutaneous medicine and surgery
2025

IL-36-driven pustulosis: Transcriptomic signatures match between generalized pustular psoriasis (GPP) and acute generalized exanthematous pustulosis (AGEP).

The Journal of allergy and clinical immunology
2025

Severe Cutaneous Adverse Reactions Following Vaccination: A Systematic Review and Meta-Analysis.

The journal of allergy and clinical immunology. In practice
2025

[Exanthematic drug eruption].

Pathologie (Heidelberg, Germany)
2025

Acute Generalized Exanthematous Pustulosis in a Patient With Crohn's Disease Being Treated for Streptococcal Pharyngitis and Sternoclavicular Joint Abscess.

Cureus
2025

Confirmation of Metformin-Induced Acute Generalized Exanthematous Pustulosis Through a Positive Dechallenge-Rechallenge Test: A Case Report and Review of Cutaneous Manifestations Associated With Metformin.

Cureus
2025

Expanding the therapeutic horizons of spesolimab: a review of off-label applications for inflammatory skin diseases.

The Journal of dermatological treatment
2025

Acute generalised exanthematous pustulosis in a child.

BMJ case reports
2025

Isotretinoin - Induced AGEP: A Case Report.

International medical case reports journal
2025

Rare acute generalized exanthematous pustulosis caused by iodixanol: A case report.

Medicine
2025

Morbilliform Eruptions: Differentiating Low-Risk Drug Eruptions, Severe Cutaneous Adverse Reactions, Viral Eruptions, and Acute Graft-Versus-Host Disease.

American journal of clinical dermatology
2025

Hypersensitivity Reactions to Anticonvulsants.

Current allergy and asthma reports
2025

Vancomycin-induced acute generalised exanthematous pustulosis.

BMJ case reports
2025

Diffuse pustules overlying brightly erythematous plaques in skin of color.

JAAD case reports
2024

Unusual Presentation of Acute Generalized Exanthematous Pustulosis with Unilateral Anterior Trunk Involvement.

Sisli Etfal Hastanesi tip bulteni
2025

Recurrent pediatric acute generalized exanthematous pustulosis with drug and infective precipitants.

JAAD case reports
2025

Acute Generalized Exanthematous Pustulosis Induced by Hyaluronic Acid Knee Injection: A Case Report.

Journal of emergency nursing
2025

Abrocitinib-induced acute generalized exanthematous pustulosis.

The Journal of dermatology
2025

Acute generalized exanthematous pustulosis showing a discrepancy between results of patch test and drug-induced lymphocyte stimulation test.

The Journal of dermatology
2024

A review on toxic epidermal necrolysis-like superficial wound lesions: Issue and challenge on 10 clinical entities.

International wound journal
2024

Spectrum of offending drugs and cutaneous adverse drug reactions requiring hospitalisation in a tertiary South African hospital in TB/HIV endemic setting.

Frontiers in allergy
2024

Vancomycin and linezolid: severe cutaneous adverse reactions to drugs.

Expert opinion on drug safety
2026

Levetiracetam and severe cutaneous adverse reactions: insights from FAERS database analysis.

Expert opinion on drug safety
2024

TNF-α inhibitors as therapy for drug-induced severe cutaneous adverse reactions: a case series.

The Journal of dermatological treatment
2025

Safety concerns of aztreonam: a real-world disproportionality analysis based on FDA Adverse Event Reporting System.

Expert opinion on drug safety
2024

Hydroxychloroquine-induced acute generalized exanthematous pustulosis with HLA-typing.

Pharmacogenomics
2025

Validation of the EuroSCAR criteria for acute generalized exanthematous pustulosis: A retrospective cohort study.

Journal of the American Academy of Dermatology
2024

An Atypical Presentation of Acute Generalized Exanthematous Pustulosis Induced by Use of Meropenem: A Case Report and Literature Review.

Cureus
2024

Acute generalized exanthematous pustulosis sine pustules following semaglutide injection.

JAAD case reports
2024

Acute generalized exanthematous pustulosis induced by icotinib: a case report and literature review.

Frontiers in pharmacology
2024

Severe Acute Generalized Exanthematous Pustulosis Successfully Treated by Spesolimab.

Acta dermato-venereologica
2024

Acute generalized exanthematous pustulosis following ceftriaxone.

Indian journal of pharmacology
2024

Acute generalised exanthematous pustulosis and herpes simplex virus: a case of possible overlap.

BMJ case reports
2024

The Australasian Registry for Severe Cutaneous Adverse Reactions (AUS-SCAR) - Providing a roadmap for closing the diagnostic, patient, and healthcare gaps for a group of rare drug eruptions.

The World Allergy Organization journal
2024

Clinical characteristics, treatment and outcome of clindamycin induced acute generalized exanthematous pustulosis.

Archives of dermatological research
2024

Denosumab-induced Acute Generalized Exanthematous Pustulosis.

Acta dermato-venereologica
2024

Rapid Improvement in Refractory Acute Generalized Exanthematous Pustulosis With Spesolimab.

JAMA dermatology
2024

Antibiotic-induced severe cutaneous adverse reactions: a single-center retrospective study over ten years.

Frontiers in immunology
2024

Acute generalized exanthematous pustulosis triggered by COVID-19.

Dermatology online journal
2025

Acute generalized exanthematous pustulosis and generalized pustular psoriasis: not so different differentials?

International journal of dermatology
2024

Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management.

Journal of the European Academy of Dermatology and Venereology : JEADV
2024

Concurrent Presentation of Eczema Herpeticum and Acute Localized Exanthematous Pustulosis in a Patient With Atopic Dermatitis: A Rare Dermatological Convergence.

Cureus
2024

Delayed Skin Testing for Systemic Medications: Helpful or Not?

The journal of allergy and clinical immunology. In practice
2024

Acute generalized exanthematous pustulosis secondary to dose-related turmeric supplementation.

Proceedings (Baylor University. Medical Center)
2024

Eczema herpeticum in an immunocompetent man.

Diagnostic microbiology and infectious disease
2024

Drug Reaction with Eosinophilia and Systemic Symptoms Induced by Diosmin and Hesperidin: A Case Report.

Clinical, cosmetic and investigational dermatology
2024

Evolution of the spectrum of drugs associated with acute generalized exanthematous pustulosis over time: A pharmacovigilance study.

Journal of the American Academy of Dermatology
2024

Lower extremity purpura as an uncommon presentation of acute generalized exanthematous pustulosis (AGEP).

International journal of dermatology
2024

COVID-19 and Autoimmunity in Dermatology: A Moroccan Case Series and Literature Review.

Cureus
2024

An unusual adverse effect during crusted scabies treatment.

Clinical case reports
2024

Severe cutaneous adverse reactions.

Nature reviews. Disease primers
2024

Recognizing rare rashes: A case of acute generalized exanthematous pustulosis.

JAAPA : official journal of the American Academy of Physician Assistants
2024

Genetic analysis of different subtypes of aseptic pustulosis in the Chinese population.

Clinical and experimental dermatology
2024

IL36RN mutations in Chinese patients with acute generalized exanthematous pustulosis.

International journal of dermatology
2024

Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens.

Dermatitis : contact, atopic, occupational, drug
2024

A rare case of acute generalized exanthematous pustulosis induced by gadobutrol.

Contact dermatitis
2024

Evaluation of the frequency and characteristics of drug hypersensitivity reactions in hospitalized children: Real life-cohort study.

The World Allergy Organization journal
2024

Icodextrin-induced acute generalized exanthematous pustulosis in a patient with peritoneal dialysis.

Nephrology (Carlton, Vic.)
2024

A Case of Diltiazem-Induced Pustular Rash in an 83-Year-Old Female.

Case reports in dermatological medicine
2024

Case Report: Kawasaki disease associated with acute generalized exanthematous pustulosis secondary to carbocysteine.

Frontiers in pediatrics
2024

Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.

The Australasian journal of dermatology
2024

A case of acute generalized exanthematous pustulosis caused by eperisone hydrochloride.

European journal of dermatology : EJD
2024

Severe cutaneous adverse reactions in a tertiary care center in Jamaica.

JAAD international
2024

First episode of generalized pustular psoriasis or acute generalized exanthematous pustulosis? A case study.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2024

Celecoxib-induced acute generalized exanthematous pustulosis: uncommon and under-recognized side effect.

EXCLI journal
2024

Differentiating generalized pustular psoriasis from acute generalized exanthematous pustulosis.

Journal of the American Academy of Dermatology
2024

Generalized Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, and Other Pustular Reactions: A Clinical Review.

Dermatologic clinics
2024

Hydroxychloroquine-induced acute generalized exanthematous pustulosis (AGEP) treated with secukinumab.

Journal of the European Academy of Dermatology and Venereology : JEADV
2024

A case report of terbinafine-induced acute generalized exanthematous pustulosis in a striking photodistributed pattern.

SAGE open medical case reports
2024

Exanthematous Pustulosis Restricted to Striae Distensae.

Journal of cutaneous medicine and surgery
2024

Acute Generalized Exanthematous Pustulosis Induced by a Jellyfish Sting (Rhizostoma pulmo).

Dermatitis : contact, atopic, occupational, drug
2024

Multiple drug hypersensitivity syndrome manifesting as acute generalised exanthematous pustulosis: A rare case report.

Contact dermatitis
2025

Ethical considerations in the management of drug severe cutaneous adverse reactions.

Journal of the American Academy of Dermatology
2023

Acute Generalized Exanthematous Pustulosis in a Hemodialysis Patient.

Cureus
2024

Medication Associations With Severe Cutaneous Adverse Reactions: A Case/Non-Case Analysis Using the FDA Adverse Event Reporting System.

Journal of cutaneous medicine and surgery
2025

Severe cutaneous adverse drug reactions: incidence, clinical characteristics, treatment, and outcome in pediatric patients.

Asian Pacific journal of allergy and immunology
2024

Unusual cutaneous adverse reaction to an erectile dysfunction drug: A case report.

Urology case reports
2023

An observational study of severe cutaneous adverse reactions at a tertiary care teaching hospital.

Medical journal, Armed Forces India
2024

Generalized pustulosis following Covid 19 vaccination in a patient in treatment with adalimumab.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
2024

Acute generalized exanthematous pustulosis: Analysis of cases managed in a Tunisian tertiary hospital.

Therapie
2023

Marginal corneal infiltrates as an ocular manifestation of acute generalized exanthematous pustulosis.

American journal of ophthalmology case reports
2023

Acute generalized exanthematous pustulosis caused by hydroxychloroquine in a patient with rheumatoid arthritis and CARD14 mutation: Case report.

Medicine
2024

Acute localised exanthematous pustulosis (ALEP)-induced by ioversol.

Contact dermatitis
2024

Cutaneous adverse drug reactions.

Therapie
2024

Acute generalized exanthematous pustulosis induced by Ambroxol confirmed by positive skin tests.

Contact dermatitis
2024

Clinicopathological characteristics of cutaneous complications following COVID-19 vaccination: A case series.

Journal of cosmetic dermatology
2024

Rapid Clearance of Corticosteroid-Resistant Targetoid Acute Generalized Exanthematous Pustulosis Using an IL-17A Inhibitor: A Case Report.

Journal of investigational allergology &amp; clinical immunology
2023

Association between HLA alleles and beta-lactam antibiotics-related severe cutaneous adverse reactions.

Frontiers in pharmacology
2024

A case of acute localized exanthematous pustulosis following COVID-19 infection.

The Journal of dermatology
2024

Characteristics of mild and severe apalutamide-related cutaneous adverse events in patients with prostate cancer: A review of the literature.

The Journal of dermatology
2023

Guideline for allergological diagnosis of drug hypersensitivity reactions: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) in cooperation with the German Dermatological Society (DDG), the Association of German Allergologists (ÄDA), the German Society for Pediatric Allergology (GPA), the German Contact Dermatitis Research Group (DKG), the German Society for Pneumology (DGP), the German Society of Otorhinolaryngology, Head and Neck Surgery, the Austrian Society of Allergology and Immunology (ÖGAI), the Austrian Society of Dermatology and Venereology (ÖGDV), the German Academy of Allergology and Environmental Medicine (DAAU), and the German Documentation Center for Severe Skin Reactions (dZh).

Allergologie select
2023

Naltrexone-induced acute generalized exanthematous pustulosis.

JAAD case reports
2023

A Rare Dermatologic Reaction in an Adult Patient Following Coronary Angiography: Acute Generalized Exanthematous Pustulosis.

The journal of Tehran Heart Center
2023

Pustular Eruption following COVID-19 Vaccination: A Narrative Case-Based Review.

Vaccines
2023

Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.

Recent advances in inflammation &amp; allergy drug discovery
2023

Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice.

Annales de dermatologie et de venereologie
2023

Acute generalized exanthematous pustulosis induced by exemestane during adjuvant radiotherapy for breast cancer.

Medicina clinica
2023

Immune Reactions in Major Types of Oncological Treatment.

International journal of molecular sciences
2023

Hydroxychloroquine-induced repetitive atypical pustular drug eruptions in the same patient separated by 12 years.

Clinical case reports
2023

Acute generalized exanthematous pustulosis secondary to mianserin with liver involvement.

European journal of dermatology : EJD
2023

Acute generalized exanthematous pustulosis associated with clindamycin in a patient with Hailey-Hailey disease.

Journal of cutaneous pathology
2024

Azathioprine hypersensitivity: A Sweet-like syndrome.

International journal of rheumatic diseases
2023

Acute generalized exanthematous pustulosis with systemic involvement.

Journal of osteopathic medicine
2023

Drug Hypersensitivity Reactions.

Immunology and allergy clinics of North America
2024

Acquired cutis laxa secondary to acute generalized exanthematous pustulosis: A case report and mini-review of literature.

The Journal of dermatology
2023

[Identification of cutaneous adverse drug reactions].

La Revue du praticien
2023

Deadly drug rashes: Early recognition and multidisciplinary care.

Cleveland Clinic journal of medicine
2023

A case of acute generalized exanthematous pustulosis following COVID-19 infection and remdesivir.

Clinical case reports
2023

Acute localized exanthematous pustulosis induced by fosfomycin.

JAAD case reports
2023

Key factors predicting the in-hospital mortality of patients with severe cutaneous adverse reactions in Thailand.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023

Severe Cutaneous Adverse Drug Reactions at a Tertiary Care Center in Saudi Arabia.

Dermatology research and practice
2023

Sorafenib-Induced Acute Generalized Exanthematous Pustulosis.

Dermatology practical &amp; conceptual
2023

Current understanding of genetic associations with delayed hypersensitivity reactions induced by antibiotics and anti-osteoporotic drugs.

Frontiers in pharmacology
2023

Acute Generalized Exanthematous Pustulosis: Clinical Features, Differential Diagnosis, and Management.

American journal of clinical dermatology
2023

Acute generalized exanthematous pustulosis complicated by cutaneous small vessel vasculitis: A case report and literature review.

The Australasian journal of dermatology
2024

Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.

Current drug safety
2023

Clinical features of acute generalized exanthematous pustulosis caused by hydroxychloroquine in rheumatology patients and exploration of CARD14 gene mutations.

Frontiers in medicine
2023

Acute generalized exanthematous pustulosis in a patient with COVID-19 infection.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023

Varenicline-induced drug eruption: case and review of the literature.

Dermatology online journal
2023

Concurrent acute generalized exanthematous pustulosis in siblings.

Pediatric dermatology
2023

Severe Cutaneous Adverse Reaction Caused by Carbamazepine and Levofloxacin After Varicella Zoster Virus Infection.

Infection and drug resistance
2023

Cutaneous candidiasis mimicking acute generalized exanthematous pustulosis: A case report.

SAGE open medical case reports
2023

A Case Report of Possibly Related Acute Generalized Exanthematous Pustulosis with Staphylococcus pettenkoferi.

Clinical, cosmetic and investigational dermatology
2023

A Case of Acute Generalized Exanthematous Pustulosis Induced by Ceftriaxone.

Cureus
2022

Generalized Pustular Figurate Erythema in Patients with COVID-19 Treated with Hydroxychloroquine: A Systematic Review.

Acta dermatovenerologica Croatica : ADC
2023

Acute Localized Exanthematous Pustulosis Induced by a Spider Bite.

Dermatitis : contact, atopic, occupational, drug
2023

Acute Localized Exanthematous Pustulosis (ALEP) Caused by Topical Application of Minoxidil.

Journal of clinical medicine
2023

Acute generalized exanthematous pustulosis: Clinico-biological profile and inducing drugs in 83 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV
2023

Acute Generalized Exanthematous Pustulosis: Clinical Characteristics, Pathogenesis, and Management.

Dermatology (Basel, Switzerland)
2023

Delayed Drug Hypersensitivity Reactions: Molecular Recognition, Genetic Susceptibility, and Immune Mediators.

Biomedicines
2023

Terbinafine Induced Acute Generalized Exanthematous Pustulosis Treated with Adalimumab: Recalcitrant to Systemic Corticosteroid Therapy.

Clinical, cosmetic and investigational dermatology
2022

The Man of a Thousand Pustules: A Case About Acute Generalized Exanthematous Pustulosis.

Cureus
Ver todos os 702 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Pustulose exantemática generalizada aguda.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Pustulose exantemática generalizada aguda

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Acute Generalized Exanthematous Pustulosis in a Neonate Following Hepatitis B Vaccination: A Case Report.
    Sage open pediatrics· 2026· PMID 41773273mais citado
  2. The Hidden Perils of Allopurinol: A Systematic Review of Allopurinol-Induced DRESS (Drug Reaction With Eosinophilia and Systemic Symptoms) Syndrome.
    Cureus· 2026· PMID 41868441mais citado
  3. A Systematic Review of Pediatric Acute Generalized Exanthematous Pustulosis.
    Pediatric dermatology· 2026· PMID 41802944mais citado
  4. Acute Generalized Exanthematous Pustulosis: An Integrated Study of 503 Cases with Emphasis on Drug Culprits, Clinical Features, Diagnosis and Treatment.
    Journal of inflammation research· 2026· PMID 41783151mais citado
  5. Iodinated Contrast-Induced AGEP and ALEP: Recognition, Diagnosis, and Management.
    International journal of dermatology· 2026· PMID 41724881mais citado
  6. Concurrent Drug-induced Rowell Syndrome and Acute Generalized Exanthematous Pustulosis.
    Acta Derm Venereol· 2026· PMID 41989074recente
  7. A 69-year-old man with acute generalized exanthematous pustulosis.
    CMAJ· 2026· PMID 41942143recente
  8. An Unusual Case of Drug-Induced Hypersensitivity Syndrome With Multiple Atypical Histopathologic Findings.
    Am J Dermatopathol· 2026· PMID 41941310recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:293173(Orphanet)
  2. MONDO:0017384(MONDO)
  3. GARD:21164(GARD (NIH))
  4. Busca completa no PubMed(PubMed)
  5. Q1980528(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Pustulose exantemática generalizada aguda
Compêndio · Raras BR

Pustulose exantemática generalizada aguda

ORPHA:293173 · MONDO:0017384
Prevalência
Unknown
Herança
Multigenic/multifactorial, Not applicable
CID-10
L27.0 · Erupção cutânea generalizada devida a drogas e medicamentos
Início
All ages
Prevalência
0.0 (Worldwide)
MedGen
UMLS
C0853331
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades